Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELOWEN-2: Enpatoran in Cutaneous Lupus Erythematosus
NCT07355218Phase 3Recruiting
- Sponsor
- EMD Serono
- Start
- Apr 2026
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of enpatoran in cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE), sponsored by EMD Serono. Started Apr 2026; status: recruiting.
02
Drugs
enpatoran
03
Conditions
cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07355218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07355218.